| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. | Chief Financial Officer | Common Stock | 108,484 | $1,562,169 | $14.40 | 11 Dec 2025 | Direct |
| Aardvark Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 209,826 | 11 Jun 2025 | Direct | ||
| Aardvark Therapeutics, Inc. | Chief Financial Officer | Series C Convertible Preferred Stock | 0 | 14 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | 11 Dec 2025 | 1 | +$43,200 | 4 | Chief Financial Officer | 12 Dec 2025, 20:30 |
| AARD | Aardvark Therapeutics, Inc. | 09 Sep 2025 | 1 | +$48,440 | 4 | Chief Financial Officer | 10 Sep 2025, 17:36 |
| AARD | Aardvark Therapeutics, Inc. | 11 Jun 2025 | 1 | $0 | 4 | Chief Financial Officer | 13 Jun 2025, 16:05 |
| AARD | Aardvark Therapeutics, Inc. | 14 Feb 2025 | 3 | +$160,000 | 4 | Chief Financial Officer | 19 Feb 2025, 16:30 |
| AARD | Aardvark Therapeutics, Inc. | 12 Feb 2025 | 0 | $0 | 3 | Chief Financial Officer | 12 Feb 2025, 19:24 |